No unsubstantiated superiority claims (better, more effective, safer, broader use)

AI-verifiedblockerBinding lawRaised as a question — a person decides

Rule

An ad may not contain a representation or suggestion, not approved or permitted for use in the labeling, that a drug is better, more effective, useful in a broader range of conditions or patients, safer, or has fewer, less frequent, or less serious side effects or contraindications than has been demonstrated by substantial evidence or substantial clinical experience. This applies whether or not the representation is made by comparison with other drugs or treatments, and whether or not it is made directly or through published or unpublished literature, quotations, or other references.

Check

First determine whether the labeling approves or permits the superiority-type representation (better, more effective, broader use, safer, fewer/less serious side effects or contraindications). If the labeling does not approve or permit it, then assess whether the representation is demonstrated by substantial evidence or substantial clinical experience; a gap is a violation. This applies regardless of whether the representation is made by comparison with other drugs or treatments, and regardless of whether it is made directly or through published or unpublished literature, quotations, or other references.

Escalate when

Whether the representation is approved or permitted in the labeling is ambiguous, or adequacy of the supporting substantial evidence or clinical experience for the specific superiority claim is uncertain.

Where this comes from

21 CFR 202.1(e)(6)(i). The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

…resentations or material with respect to consequences that may result from the use of the drug as recommended or suggested in the advertisement. (6) Advertisements that are false, lacking in fair balance, or otherwise misleading. An advertisement for a prescription drug is false, lacking in fair balance, or otherwise misleading, or otherwise violative of section 502(n) of the act, among other reasons, if it: (i) Contains a representation or suggestion, not approved or permitted for use in the labeling, that a drug is better, more effective, useful in a broader range of conditions or patients (as used in this section patients means humans and in the case of veterinary drugs, other animals), safer, has fewer, or less incidence of, or less serious side effects or contraindications than has been demonstrated by substantial evidence or substantial clinical experience (as described in paragraphs (e)(4)(ii) (b) and (c) of this section) whether or not such representations are made by comparison with other drugs or treatments, and whether or not such a representation or suggestion is made directly or through use of published or unpublished literature, quotations, or other references. (ii) Contains a drug comparison that represents or suggests that a drug is safer or more effect…

Open the original at these words on ecfr.gov ↗Read our full copy →

Document: 21 CFR 202.1
Version: 2026-09-16 — the link above is pinned to this date, so it shows the text as it stood then
Retrieved: 2026-09-21 from www.ecfr.gov
Fingerprint: a542640a872b3f2702d549e8…

Applies when

Naturepromotional

How this rule was checked

Citation proven by script and passed an independent verifier running on a different model. Not yet confirmed by a human.

Drafted
claude-code:sonnet · 2026-09-21
Independent verification — revise
claude-code:opus · 2026-09-21
Reviewer's reasons
- The core of the rule is supported: (e)(6)(i) is binding regulation text making an ad false or misleading if it contains a representation or suggestion that a drug is better, more effective, useful in a broader range of conditions or patients, safer, or has fewer/less serious side effects than has been demonstrated by substantial evidence or substantial clinical experience.
- The rule's final clause — 'and such claim need not be approved in labeling to be prohibited' — is not supported and inverts the source. The quoted text reads 'Contains a representation or suggestion, NOT APPROVED OR PERMITTED FOR USE IN THE LABELING, that a drug is better...'. That phrase is a limiting condition on the violation, not a note that labeling status is irrelevant. As written the rule reads the limitation out of the regulation and makes the prohibition broader than the source, which would flag claims that are in fact approved or permitted in the labeling.
- The rule also drops two clarifiers that are part of the same sentence and bear directly on how a reviewer applies it: the prohibition holds 'whether or not such representations are made by comparison with other drugs or treatments' and 'whether or not such a representation or suggestion is made directly or through use of published or unpublished literature, quotations, or other references.' Their absence narrows the check in practice even while the added clause broadens it.
- Atomic: despite the erroneous trailing clause, this remains one checkable requirement (an unsubstantiated superiority/breadth/safety representation), not a bundle of independent ones.
- determinism 'judgment' is right: whether an ad 'suggests' superiority, and whether substantial evidence or substantial clinical experience supports it, are matters of impression and adequacy, not literal match.
- authority 'binding' is correct; severity 'blocker' is defensible under section 502(n); locator 21 CFR 202.1(e)(6)(i) matches the quoted text; applies_when 'promotional' is justified.
- Note also that the Effective Date Note's alternative text concerns (e)(6)(ii) and (vii), not (i), so it does not bear on this rule.
Revised by the drafter
claude-code:sonnet · 2026-09-21
Independent verification — pass
claude-code:opus · 2026-09-21
Reviewer's reasons
- The quote is 202.1(e)(6)(i), which sits under the (e)(6) chapeau declaring that an advertisement 'is false, lacking in fair balance, or otherwise misleading ... if it' does the listed thing. Because (e)(6) is conclusive (unlike (e)(7)'s 'may be'), stating the rule as a prohibition is not an overstatement.
- The rule preserves both limbs of the source: the representation must be one 'not approved or permitted for use in the labeling' AND must exceed what has been demonstrated by substantial evidence or substantial clinical experience. The check sequences these correctly instead of collapsing to a single prong, which is the usual failure here.
- The 'whether or not by comparison with other drugs' and 'directly or through literature, quotations, or other references' clauses are carried over verbatim in substance and are part of the same enumerated item, not a separate requirement.
- The enumerated superiority forms (better, more effective, broader range of conditions or patients, safer, fewer/less incidence/less serious side effects or contraindications) are alternative ways of satisfying one enumerated violation, so the rule remains a single checkable requirement.
- 'Judgment' is correct — whether a claim is a superiority suggestion and whether the evidence is 'substantial' cannot be resolved by presence/absence. Authority 'binding' and severity 'blocker' are both appropriate for a (e)(6) conclusive-violation item.